• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation.
Conclusion: DOAC discontinuation rates varied significantly and appeared related to drug-specific side effects, patient-initiated discontinuation, and bleeding. We observed longer-term administration of apixaban, suggesting that this drug is better tolerated than dabigatran or rivaroxaban. PMID: 32011180 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 5, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Inappropriate non-vitamin  K antagonist oral anticoagulants prescriptions: be cautious with dose reductions.
CONCLUSION: An incorrect prescription occurred more often in the reduced-dose NOAC group. Clinical parameters such as renal function are often unknown whilst these are essential to determine the right NOAC and dose. PMID: 30949972 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - April 3, 2019 Category: Cardiology Authors: Jacobs MS, van Hulst M, Campmans Z, Tieleman RG Tags: Neth Heart J Source Type: research

Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in the Netherlands.
CONCLUSION: Dabigatran treatment was as a predictor for lower cardiology costs and lower total hospital care costs in AF patients that initiated oral anticoagulation. PMID: 28766370 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - August 4, 2017 Category: Health Management Tags: J Med Econ Source Type: research